Novartis Institutes for BioMedical Research

Novartis Institutes for BioMedical Research. It is the global pharmaceutical research organization of the multinational Novartis, dedicated to discovering innovative medicines. Established in the early 21st century, it operates as a network of research centers focused on translating scientific discoveries into transformative therapies for patients. Its work spans multiple therapeutic areas and leverages advanced technologies in drug discovery and development.

History and organization

The Novartis Institutes for BioMedical Research was formed in 2002 following the merger that created Novartis, consolidating research from legacy companies Ciba-Geigy and Sandoz. Under the leadership of its first president, Mark Fishman, the organization was restructured to operate more like an academic biotech startup, emphasizing collaboration over traditional corporate silos. This model organized scientists into small, disease-focused teams across institutes such as the Novartis Institute for Tropical Diseases and the Friedrich Miescher Institute for Biomedical Research. A significant strategic move was the relocation of its global research headquarters from Basel to Cambridge, Massachusetts in the United States, placing it at the heart of the Kendall Square biomedical innovation ecosystem.

Research focus and therapeutic areas

The organization's research is strategically directed at high-unmet medical needs across a broad spectrum of diseases. Core therapeutic areas include oncology, where it investigates targeted therapies and immuno-oncology; neuroscience, focusing on conditions like Alzheimer's disease, Parkinson's disease, and multiple sclerosis; and autoimmune diseases such as psoriasis and rheumatoid arthritis. Additional major focuses encompass cardiovascular and metabolic diseases, ophthalmology, and respiratory diseases. Research integrates cutting-edge platforms in genomics, chemical biology, and data science to identify novel drug targets and biological pathways.

Key scientific contributions and discoveries

Scientists at the Novartis Institutes for BioMedical Research have been instrumental in several landmark drug discoveries. A major breakthrough was the development of imatinib (Gleevec/Glivec), a pioneering tyrosine kinase inhibitor that revolutionized the treatment of chronic myeloid leukemia and certain gastrointestinal stromal tumors. In oncology, the institute also contributed to ceritinib and ribociclib. In immunology, the discovery and development of secukinumab (Cosentyx) provided a first-in-class treatment for psoriasis, ankylosing spondylitis, and psoriatic arthritis. Further significant contributions include fingolimod (Gilenya) for multiple sclerosis and canakinumab (Ilaris) for rare auto-inflammatory syndromes.

Collaborations and partnerships

The organization maintains an extensive network of external collaborations to accelerate innovation. It partners with leading academic institutions like the Broad Institute, Harvard University, and the University of Pennsylvania on foundational research. Strategic alliances with biotechnology companies, such as those with MorphoSys and Intellia Therapeutics, access novel technology platforms like antibody discovery and CRISPR gene editing. It also engages in major public-private partnerships, including initiatives with the Bill & Melinda Gates Foundation on diseases like malaria and tuberculosis, and with the Structural Genomics Consortium on open-source drug discovery.

Facilities and global presence

The global research headquarters is a state-of-the-art facility in Cambridge, Massachusetts, designed to foster interdisciplinary collaboration among thousands of scientists. In Switzerland, major research sites are located in Basel and at the Friedrich Miescher Institute. The organization operates the Novartis Institute for Tropical Diseases in Singapore, focusing on neglected diseases. Additional significant research centers are situated in Emeryville, California (focused on genomics and cell therapy), Shanghai (the Novartis Institutes for BioMedical Research in China), and Basel. These facilities collectively house advanced laboratories for high-throughput screening, structural biology, and translational research. Category:Novartis Category:Medical and health research institutes Category:Biotechnology companies Category:Research and development in Switzerland Category:Research and development in the United States